Compare PENG & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PENG | CDNA |
|---|---|---|
| Founded | 1988 | 1998 |
| Country | United States | United States |
| Employees | 2900 | N/A |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 1.1B |
| IPO Year | N/A | 2007 |
| Metric | PENG | CDNA |
|---|---|---|
| Price | $47.96 | $21.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $27.78 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 2.9M | 604.0K |
| Earning Date | 04-01-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $14.55 | $16.01 |
| Revenue Next Year | $16.14 | $11.31 |
| P/E Ratio | ★ $87.50 | $408.80 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $16.04 | $10.96 |
| 52 Week High | $53.27 | $23.24 |
| Indicator | PENG | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 76.44 | 55.59 |
| Support Level | $18.38 | $15.80 |
| Resistance Level | $53.27 | $21.20 |
| Average True Range (ATR) | 3.85 | 1.01 |
| MACD | 0.43 | -0.16 |
| Stochastic Oscillator | 76.43 | 56.80 |
Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.